5,223 Shares in Illumina, Inc. $ILMN Acquired by Stonehage Fleming Financial Services Holdings Ltd

Stonehage Fleming Financial Services Holdings Ltd bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,223 shares of the life sciences company’s stock, valued at approximately $918,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Proficio Capital Partners LLC purchased a new position in Illumina during the second quarter worth approximately $941,000. Transamerica Financial Advisors LLC acquired a new position in shares of Illumina in the 2nd quarter valued at $152,000. Corient Private Wealth LP purchased a new stake in shares of Illumina during the 2nd quarter valued at $16,035,000. PointState Capital LP purchased a new stake in shares of Illumina during the 2nd quarter valued at $151,602,000. Finally, Bamco Inc. NY acquired a new stake in shares of Illumina during the 2nd quarter worth $39,930,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $227.69 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The company has a market cap of $34.38 billion, a PE ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45. The company’s fifty day simple moving average is $192.98 and its 200-day simple moving average is $155.18. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the company earned $1.19 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Transactions at Illumina

In related news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 2,034,688 shares of company stock worth $417,970,281. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Citigroup increased their target price on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Stifel Nicolaus boosted their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Royal Bank Of Canada upped their price target on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Barclays raised their price objective on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. Finally, Piper Sandler reiterated an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.